In 2019, the field of personalized medicine continued to grow with the market launch of more than two dozen drugs targeting novel genomic alterations and numerous genetic tests to determine whether patients are at risk for serious diseases like cancer, and whether they are likely to respond to therapy.
The mechanisms of these newer drugs and the algorithms underlying the latest tests reflect the field’s increasing understanding of complex disease biology. “2019 has been a pivotal year and we are seeing exponential growth in precision medicine,” said Jordan Clark, chief commercial officer at diagnostics data analytics company Diaceutics.
To read the full article, click here.